Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis
This study has been terminated.
(The PI left and then the PI who would be taking over has left. No other investigator wanted to take the study since not sponsored)
Sponsor:
Indiana University
Information provided by (Responsible Party):
Indiana University
ClinicalTrials.gov Identifier:
NCT01442454
First received: September 26, 2011
Last updated: February 29, 2016
Last verified: February 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to correlate Endoscopic Ultrasound (EUS) criteria for chronic pancreatitis with surgical pathology.
| Condition | Intervention |
|---|---|
|
Chronic Pancreatitis |
Other: chronic pancreatitis |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis: A Prospective Correlation With Intraoperative Findings and Surgical Pathology |
Resource links provided by NLM:
Further study details as provided by Indiana University:
| Enrollment: | 100 |
| Study Start Date: | October 2010 |
| Study Completion Date: | September 2014 |
| Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| Chronic Pancreatitis |
Other: chronic pancreatitis
No intervention, subjects followed through surgery
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients undergoing EUS
Criteria
Patients who are eligible are individuals who have:
- normal pancreas
- suspected chronic pancreatitis
- established chronic pancreatitis (by ERCP, MRI, previous EUS, CT)
- pancreatic cancer
Patients who are not eligible are individuals who have:
• an uncorrectable coagulopathy (platelet <50,000, INR>1.5), or bleeding disorder, or are unable to discontinue anticoagulation 5-7 days prior to EUS (aspirin and bridging therapy with lovenox are allowed, clopidogrel is not allowed)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01442454
Please refer to this study by its ClinicalTrials.gov identifier: NCT01442454
Locations
| United States, Indiana | |
| Indiana University Hospital | |
| Indianapolis, Indiana, United States, 46202 | |
Sponsors and Collaborators
Indiana University
More Information
| Responsible Party: | Indiana University |
| ClinicalTrials.gov Identifier: | NCT01442454 History of Changes |
| Other Study ID Numbers: | 1008-15 |
| Study First Received: | September 26, 2011 |
| Last Updated: | February 29, 2016 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Indiana University:
|
chronic pancreatitis |
Additional relevant MeSH terms:
|
Pancreatitis Pancreatitis, Chronic Pancreatic Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on September 26, 2016